We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.


Medtronic offers medical products and therapies for the treatment of cardiac and vascular diseases, diabetes, and neu... read more Featured Products: More products

Download Mobile App

Revolutionary System Maps and Ablates Atrial Arrhythmias and Provides Real-Time Feedback

By HospiMedica International staff writers
Posted on 17 Mar 2023
Print article
Image: First of its kind, all-in-one Sphere-9 Catheter with pulsed field ablation (Photo courtesy of Medtronic)
Image: First of its kind, all-in-one Sphere-9 Catheter with pulsed field ablation (Photo courtesy of Medtronic)

Atrial fibrillation (AFib) is the most prevalent atrial arrhythmia globally, affecting approximately 60 million people worldwide. By 2030, an estimated five million more patients will be diagnosed each year. Atrial arrhythmias, including AFib, can lead to severe complications such as heart failure, stroke, and an increased risk of mortality. To address these challenges, the first-of-its-kind catheter with pulsed-field ablation, radiofrequency, and high-density mapping that is integrated with an intuitive mapping and navigation platform improves efficiency and enhances the safety of ablation procedures for patients.

The Affera Mapping and Ablation System from Medtronic plc (Dublin, Ireland), which includes the Sphere-9 Catheter and the Affera Prism-1 Mapping Software, marks a breakthrough in electrophysiology by integrating the Sphere-9 pulsed field ablation (PFA), radiofrequency (RF), and high density (HD) mapping catheter, which maps and ablates atrial arrhythmias (fast, abnormal heart rhythms) and provides real-time feedback using its intuitive mapping and navigation software.

The Sphere-9 Catheter, combined with the integrated mapping and navigation system, instantly generates sophisticated electro-anatomical maps, enabling physicians to administer wide-area focal ablation lesions of choice between RF or PFA, depending upon the requirements of the patient and procedure. Considering its size, the all-in-one catheter's nitinol 9mm ablation tip will need fewer focal ablation lesion applications that can reduce procedure times as compared to standard irrigated ablation catheters. The intuitive mapping software provides a highly optimized user experience by offering streamlined insights and feedback to support procedure performance.

Medtronic has received CE (Conformité Européenne) Mark for the Affera Mapping and Ablation System, based on results from clinical studies assessing the safety and performance of the Sphere-9 Catheter and Mapping System. The CE Mark approval comes on the back of the December 2022 announcement of the completion of enrollment for the Affera SPHERE Per-AF Clinical Trial, a randomized, controlled U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) pivotal trial. The SPHERE PER-AF IDE trial aims to investigate the safety and efficacy of the Affera Mapping and Ablation System in treating persistent atrial fibrillation. Currently, the trial is in its 12-month follow-up phase. The Affera Mapping and Ablation System will be available for commercial use in Europe by the first half of 2023, whereas it is still in the investigational stage in the U.S.

"The revolutionary Affera Mapping and Ablation System combined with the novel Sphere-9 Catheter represent a great advancement in the field of HD mapping and focal ablation," said Khaldoun Tarakji, M.D., MPH, vice president, chief medical officer, Cardiac Ablation Solutions business, which is part of the Cardiovascular Portfolio at Medtronic. "Current technologies require the use of separate HD mapping and ablation catheters. The ability to map, ablate, and validate with the Sphere-9 Catheter enables the physician to eliminate the need to exchange catheters and empowers them to choose the energy source, whether RF or PF, based on the patient's needs. All this leads to improving efficiency and most importantly, enhancing the safety of ablation procedures for our patients."

Related Links:
Medtronic plc

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Silver Member
Compact 14-Day Uninterrupted Holter ECG
Non-Contact Infrared Forehead Thermometer
Propper IR Thermometer

Print article


Critical Care

view channel
Image: This study is significant as it addresses a treatment approach that has not been extensively studied before (Photo courtesy of 123RF)

Study Confirms Safety of DCB-Only Strategy for Treating De Novo Left Main Coronary Artery Disease

There has been a lack of extensive research on the use of drug-coated balloon (DCB)-only strategy for the treatment of de novo left main coronary artery disease, especially in high bleeding risk (HBR) patients.... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The Quantra Hemostasis System has received US FDA special 510(k) clearance for use with its Quantra QStat Cartridge (Photo courtesy of HemoSonics)

Critical Bleeding Management System to Help Hospitals Further Standardize Viscoelastic Testing

Surgical procedures are often accompanied by significant blood loss and the subsequent high likelihood of the need for allogeneic blood transfusions. These transfusions, while critical, are linked to various... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.